Retatrutide dosage: the trial step-ups

Reviewed 12 sourcesPublished by PepVault

Retatrutide dosage in trials: a 2 mg weekly start, a step up every four weeks to 4, 9 or 12 mg in phase 3, what phase 2 tested, and why no label exists.

A smiling woman in a sage-green training top on a sunny balcony bench, holding a glass of water, a towel and plants beside her
Last reviewed
Sources
12
Questions
7
Compounds
2

The short answer

In the phase 3 TRIUMPH-1 and TRIUMPH-2 trials, retatrutide started at 2 mg once weekly and stepped up every four weeks, through 4, 6 and 9 mg, to a target of 4, 9 or 12 mg, so the top dose arrived at week 17. Phase 2 tested 0.5 to 12 mg, with climbs that started at 2 or 4 mg. These are research figures, not a dose for anyone.

Every number checked at its primary source · · 12 sources · How we research

Evidence: Randomised phase 1b, phase 2 and phase 3 trials in people, published in The Lancet, NEJM and Nature Medicine, with the phase 3 step schedule and some figures from Lilly's releases and the TRIUMPH design paper; retatrutide is investigational and not approved.

A smiling woman in a sage-green training top on a sunny balcony bench, holding a glass of water, a towel and plants beside her

Why does retatrutide start low and climb?

Retatrutide is one peptide that works three hormone receptors: GIP, GLP-1 and glucagon1. The first two are the incretin signals that turn appetite down, and GLP-1 also slows the stomach, so a meal feels bigger and lasts longer. That same action on the gut is where the common side effects come from, and they rise with the dose. In the phase 2 obesity trial the stomach effects were dose-related and mostly mild to moderate1, and in its liver substudy they came mainly during the weeks of dose escalation3.

So most arms in the trials climb to their dose rather than start there, and every arm in the TRIUMPH trials does11. Phase 2's results record names the reason: the climb was there to improve stomach tolerability2. The climb is slow for a second reason: retatrutide lasts. Its half-life in people is about six days, measured in a phase 1b trial6. A drug with a six-day half-life takes roughly four to five half-lives, about a month of weekly doses, to settle at a steady level, which is about the length of each step the trials used. The chart shows that build-up.

Try it

How Retatrutide builds up

An estimate from a half-life of about 6.3 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleRetatrutide in the library

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What schedule did the phase 3 TRIUMPH trials use?

In TRIUMPH-1 and TRIUMPH-2, every arm started at 2 mg once weekly and stepped up every four weeks until it reached its target710. The target was assigned at random and kept blind, so neither the participants nor the staff knew who was climbing to which dose11. The design paper describes it as a fixed escalation regimen: 16 weeks of escalation, then 64 weeks at the maintenance dose, for 80 weeks in all11.

Target doseSteps on the wayTarget reached
4 mg2 mg for four weeksWeek 5, after one step
9 mg2, 4 and 6 mg, four weeks eachWeek 13, after three steps
12 mg2, 4, 6 and 9 mg, four weeks eachWeek 17, after four steps

The steps are Lilly's published description of the TRIUMPH-1 and TRIUMPH-2 schedule710; the week each target arrives follows from a step every four weeks. They describe the research, not a protocol to copy.

TRIUMPH-1 and TRIUMPH-2 tested all three targets against placebo. TRIUMPH-3, in people with established cardiovascular disease, and TRIUMPH-4, in people with knee osteoarthritis, tested 9 and 12 mg only11. After week 80, TRIUMPH-1 ran a blinded 24-week extension for people with a BMI of 35 or more who had finished the 80 weeks and tolerated their assigned dose, in which everyone climbed to the highest dose they tolerated, 9 or 12 mg7.

What did the earlier trials test?

Phase 3 is the end of a search. The earlier trials tried lower and higher starts, smaller and bigger jumps, and fixed doses with no climb at all.

TrialWho, how longArms and their climbs
Phase 1b, 2022672 adults with type 2 diabetes, 12 weeksFixed 0.5, 1.5 and 3 mg; 3 then 6 mg; and 3, 6, 9 then 12 mg, the top doses reached by stepping up
Phase 2 obesity, 202312338 adults with obesity or overweight, 48 weeksFixed 1 mg; 4 mg from a 2 or a 4 mg start; 8 mg via 2 and 4 mg, or via 4 mg; 12 mg via 2, 4 and 8 mg
Phase 2 type 2 diabetes, 202345281 adults with type 2 diabetes, 36 weeksFixed 0.5 mg; 4 mg from a 2 mg start or with no climb; 8 mg via 2 and 4 mg, or via 4 mg; 12 mg via 2, 4 and 8 mg
TRIUMPH-1 and -2, 2026789102,339 adults without diabetes, and 1,152 with type 2 diabetes, 80 weeks4, 9 or 12 mg, each from a 2 mg start, a step every four weeks

In the phase 2 obesity trial, where a climb applied, the steps came every four weeks3, and the last of them was done by week 122. Phase 2's ladder ran 2, 4, 8 and 12 mg. Phase 3 added smaller rungs at 6 and 9 mg, and its 12 mg arm takes four steps where phase 2's took three. The phase 2 diabetes paper says its results informed the dose selection for phase 34, and the TRIUMPH design paper says the doses and escalation were chosen from the phase 1 and 2 safety and efficacy data and exposure-response modelling11.

Does the starting dose make a difference?

Yes, and phase 2 measured it directly by running the same target dose from two different starts. The obesity trial's authors report that the stomach effects were partly eased by starting at 2 mg rather than 4 mg1. The trial's posted results show the size of it, as the share of people who had nausea, in starting-dose arms of 33 to 35 people each2:

  • 4 mg target: 18% with a 2 mg start, against 36% with a 4 mg start.
  • 8 mg target: 17% with a 2 mg start, against 60% with a 4 mg start.
  • Placebo: 11%.

The diabetes trial saw the same pattern. Stomach effects ranged from 13% of people on the fixed 0.5 mg dose to 50% in the 8 mg arm that started at 4 mg, its fast climb, against 13% on placebo4. Every arm in TRIUMPH-1 and TRIUMPH-2 opens at 2 mg710.

What did each dose reach?

More dose bought more weight loss, with the gain shrinking toward the top. At 80 weeks in TRIUMPH-1, average weight loss was 17.6% on 4 mg, 23.7% on 9 mg and 25.0% on 12 mg, against 3.9% on placebo8. Had everyone stayed on treatment (Lilly's efficacy estimand), the 4 mg arm, reached with a single step, averaged 19.0%7. With type 2 diabetes, TRIUMPH-2 reached 11.9%, 16.8% and 18.8%, against 5.1% on placebo9.

The same three doses were tested as a diabetes treatment in TRANSCEND-T2D-1, a 40-week trial in adults whose type 2 diabetes was not controlled by diet and exercise alone: HbA1c fell 1.69, 1.86 and 1.94 points against 0.81 on placebo, and weight fell 11.5%, 13.9% and 15.3% against 2.6%12.

The higher targets also meant more people stopping. In TRIUMPH-1, 4.1% on 4 mg stopped because of side effects, close to placebo's 4.9%, against 6.9% on 9 mg and 11.3% on 12 mg7. In TRIUMPH-2 the rates for stopping because of side effects or death were 4%, 12% and 8%, against 5% on placebo9. The 4 mg arm traded some weight loss for a shorter climb and a stopping rate close to placebo's.

What did the trials do when a step was hard?

The schedule was fixed, but it had a safety valve. In the TRIUMPH protocols, a person whose stomach effects or eating did not improve with other measures could step back down and then try the climb again. If that still failed, a permanent dose reduction was allowed. A reduction was also allowed for anyone who reached a BMI of 22 or less, or who felt they had lost too much weight11.

The stomach effects themselves are the familiar ones of this drug class, and in TRANSCEND-T2D-1 they were generally mild to moderate and subsided over time12. What helps in the step-up weeks is ordinary: smaller meals, eating slowly and stopping at the first sign of fullness, steady fluids through the day, and more fibre and water when constipation shows up.

Commonly reported: nausea or heavy fullness in the days after each step-up that settles within one to two weeks, appetite dropping early and further at each step, often described as stronger than on tirzepatide, and some tiredness.

Is there an approved retatrutide dose?

No. Retatrutide is investigational, and Lilly states that it 'cannot be legally sold or marketed for human use'10; it is legally available only to participants in Lilly's trials7. Lilly plans to file with the FDA in the first quarter of 202710.

That means there is no prescribing information yet: no approved starting dose, no approved step schedule, no official guidance on a missed dose or on restarting after a break. Those are the things a label exists to say, and a drug carries one only once a regulator has reviewed its trials and approved it. Until then, the schedules above are what retatrutide's dosing record consists of, each set and monitored by trial clinicians.

For the rest of the story, PepVault's guide to retatrutide week by week follows the same trials through appetite, weight and side effects, and the library page at pepvault.app/peptides/retatrutide covers how it works and its timeline.

Track it in the app

Sources

  1. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. PubMed 37366315
  2. ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight (phase 2; sponsor Eli Lilly and Company). Results record. clinicaltrials.gov
  3. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. PubMed 38858523
  4. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. PubMed 37385280
  5. ClinicalTrials.gov NCT04867785. A study of LY3437943 in participants with type 2 diabetes (phase 2; sponsor Eli Lilly and Company). Results record. clinicaltrials.gov
  6. Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022. PubMed 36354040
  7. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, May 21, 2026. prnewswire.com
  8. Jastreboff AM et al.; TRIUMPH-1 Investigators. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. PubMed 42814954
  9. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PubMed 42810372
  10. Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. Press release, Sept 29, 2026. prnewswire.com
  11. Giblin K et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. PubMed 41090431
  12. Bajaj HS et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a phase 3 trial. Lancet. 2026. PubMed 42250575

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo